Mallinckrodt Patent-Cliff Exposure & CMS Drug Spending Portfolio

Mallinckrodt (St. Louis, MO): 15 reconciled FDA prescription therapies, $1.25B 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterSt. Louis, MO
Reconciled FDA Portfolio Therapies15
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2036-01-01
2024 CMS Total Public Spend$1.25B
2024 Medicare Part D Spend$1.06B
2024 Medicaid Spend$188.6M
California HCAI SB 17 Filings8 WAC filings (max 26.4% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Mallinckrodt across sibling Meru public-data platforms.